Notes
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure
Reference
Athanasakis K, et al. Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. ClinicoEconomics and Outcomes Research : 12 Oct 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S107831
Rights and permissions
About this article
Cite this article
Eplerenone cost effective for CHF in Greece. PharmacoEcon Outcomes News 764, 19 (2016). https://doi.org/10.1007/s40274-016-3468-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3468-4